| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| D412014-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $99.90 | |
| D412014-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $453.90 | |
| D412014-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,889.90 | |
| D412014-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,401.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Daratumumab (anti-CD38), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CD38, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | 2.4.99.20 | 2'-phospho-ADP-ribosyl cyclase | 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase | 2'-phospho-cyclic-ADP-ribose transferase | ADPRC 1 | ADP-ribosyl cyclase 1 | cADPr hydrolase 1 | Cyclic ADP-ribose hydrolase 1 | EC 3.2. |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | CD38 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of CD38 |
| Product Description | Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 24.5 kDa (Light Chain) & 50.3 kDa (Heavy Chain), under reducing conditions; 175.9 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 945721-28-8 |
Daratumumab (anti-CD38) (D412014) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Daratumumab (anti-CD38) (D412014). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Daratumumab (anti-CD38) (D412014) - SEC
The purity of Daratumumab (anti-CD38) (D412014) is more than 95% verified by HPLC.
Daratumumab (anti-CD38) (D412014) - ELISA
Immobilized human-CD38-ECD-Nhis at 2 μg/mL can bind Daratumumab (anti-CD38) (D412014) with the EC50 of 30.71 ng/mL.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 301 |
|---|---|
| Wikipedia | Daratumumab |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0404209 | Certificate of Analysis | Apr 08, 2024 | D412014 |
| ZJ24F0404210 | Certificate of Analysis | Apr 08, 2024 | D412014 |
| ZJ24F0404211 | Certificate of Analysis | Apr 08, 2024 | D412014 |
| 1. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.. Haematologica, 96 (2): (284-90). [PMID:21109694] [10.1021/op500134e] |
| 2. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al.. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.. J Immunol, 186 (3): (1840-8). [PMID:21187443] [10.1021/op500134e] |
| 3. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. (2011) The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.. Blood Cancer J, 1 (10): (e41). [PMID:22829073] [10.1021/op500134e] |
| 4. Sanford M, McCormack PL. (2016) A Three-Drug Combo for Multiple Myeloma.. Cancer Discov, 6 (11): (OF4). [PMID:27630127] [10.1021/op500134e] |
| 5. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e] |
| 6. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation.. J Immunol, 144 (7): (2811-5). [PMID:2319135] [10.1021/op500134e] |
| 7. Isabelle Kuhn,Esther Kellenberger,Fatouma Said-Hassane,Pascal Villa,Didier Rognan,Annelise Lobstein,Jacques Haiech,Marcel Hibert,Francis Schuber,Hélène Muller-Steffner. (2010-10-19) Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.. Bioorganic & medicinal chemistry, 18 ((22)): (7900-7910). [PMID:20951593] |
| 8. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge. (2011-01-29) Initial characterization of the human central proteome.. BMC systems biology, 5 (17-17). [PMID:21269460] |
| 9. Swarbrick JM, Graeff R, Zhang H, Thomas MP, Hao Q, Potter BV.. (2014) Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.. J Med Chem, 57 (20): (8517-8529). [PMID:25226087] [10.1021/jm501037u] |
| 10. Jacques SA, Kuhn I, Koniev O, Schuber F, Lund FE, Wagner A, Muller-Steffner H, Kellenberger E.. (2015) Discovery of Potent Inhibitors of Schistosoma mansoni NAD⁺ Catabolizing Enzyme.. J Med Chem, 58 (8): (3582-3592). [PMID:25803425] [10.1021/acs.jmedchem.5b00203] |
| 11. Becherer JD, Boros EE, Carpenter TY, Cowan DJ, Deaton DN, Haffner CD, Jeune MR, Kaldor IW, Poole JC, Preugschat F, Rheault TR, Schulte CA, Shearer BG, Shearer TW, Shewchuk LM, Smalley TL, Stewart EL, Stuart JD, Ulrich JC.. (2015) Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.. J Med Chem, 58 (17): (7021-7056). [PMID:26267483] [10.1021/acs.jmedchem.5b00992] |
| 12. Deaton DN, Haffner CD, Henke BR, Jeune MR, Shearer BG, Stewart EL, Stuart JD, Ulrich JC.. (2018) 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships.. Bioorg Med Chem, 26 (8): (2107-2150). [PMID:29576271] [10.1016/j.bmc.2018.03.021] |
| 13. States, D J DJ, Walseth, T F TF and Lee, H C HC.. (1992) Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38.. Trends in biochemical sciences, [PMID:1471258] |
| 14. Tohgo, A A and 8 more authors.. (1994) Essential cysteine residues for cyclic ADP-ribose synthesis and hydrolysis by CD38.. The Journal of biological chemistry, (18): [PMID:7961800] |
| 15. Takasawa, S S and 7 more authors.. (1993) Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP.. The Journal of biological chemistry, (15): [PMID:8253715] |
| 16. Nata, K K and 9 more authors.. (1997) Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing.. Gene, (28): [PMID:9074508] |
| 17. Yagui, K K and 13 more authors.. (1998) A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro.. Diabetologia, [PMID:9754820] |
| 18. Hillman, R Tyler RT, Green, Richard E RE and Brenner, Steven E SE.. (2004) An unappreciated role for RNA surveillance.. Genome biology, [PMID:14759258] |
| 19. Liu, Qun Q and 5 more authors.. (2005) Crystal structure of human CD38 extracellular domain.. Structure (London, England : 1993), [PMID:16154090] |
| 20. Wollscheid, Bernd B and 7 more authors.. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.. Nature biotechnology, [PMID:19349973] |
